4D Molecular Therapeutics Files 8-K Report
Ticker: FDMT · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-k
TL;DR
4D Molecular Therapeutics filed an 8-K, likely with routine updates. Check full filing for specifics.
AI Summary
On July 17, 2024, 4D Molecular Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is providing information under 'Other Events'. No specific details regarding new events, agreements, or financial transactions were disclosed in the provided excerpt.
Why It Matters
This filing signals that 4D Molecular Therapeutics is making a regulatory disclosure. Investors should review the full filing for details on any significant events that may impact the company.
Risk Assessment
Risk Level: low — The filing is a standard 8-K disclosure without immediate negative or positive financial implications presented in the excerpt.
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Registrant
- July 17, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- 001-39782 (other) — Commission File Number
- 47-3506994 (other) — IRS Employer Identification Number
- 5858 Horton Street #455 (address) — Principal executive offices
- Emeryville, CA 94608 (address) — Principal executive offices
- (510) 505-2680 (phone_number) — Registrant's telephone number
FAQ
What is the specific nature of the 'Other Events' disclosed in this 8-K filing?
The provided excerpt does not specify the nature of the 'Other Events'; it only indicates that the filing is made under this item.
When was this 8-K report filed with the SEC?
The report was filed on July 17, 2024.
What is the principal business address of 4D Molecular Therapeutics, Inc.?
The principal executive offices are located at 5858 Horton Street #455, Emeryville, CA 94608.
What is the Commission File Number for 4D Molecular Therapeutics, Inc.?
The Commission File Number is 001-39782.
What is the state of incorporation for 4D Molecular Therapeutics, Inc.?
The company is incorporated in Delaware.
Filing Stats: 1,449 words · 6 min read · ~5 pages · Grade level 14.4 · Accepted 2024-07-17 06:04:01
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share FDMT The Nasdaq
Filing Documents
- d873208d8k.htm (8-K) — 45KB
- 0001193125-24-179950.txt ( ) — 169KB
- fdmt-20240717.xsd (EX-101.SCH) — 3KB
- fdmt-20240717_lab.xml (EX-101.LAB) — 18KB
- fdmt-20240717_pre.xml (EX-101.PRE) — 11KB
- d873208d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's clinical development plans for 4D-150 and timing for the announcement of results from ongoing clinical trials. In some cases you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "expect" or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in the Company's most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 4D MOLECULAR THERAPEUTICS, INC. Date: July 17, 2024 By: /s/ Uneek Mehra Uneek Mehra Chief Financial and Business Officer